This report was first published by Endpoints News. To see the original version, click here
Sanofi has raised the curtain on data from an unsuccessful Phase 3 BTK inhibitor trial, which led to the company retreating from a form of multiple sclerosis.
According to the study’s lead investigator, several factors likely contributed to the trial’s failure. The study encountered slow enrollment and unfavorable baseline patient attributes. There was also slow disease progression, which stymied opportunities for the drug to show an impact.
您已阅读14%（534字），剩余86%（3221字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。